JFG
GALT icon

Jefferies Financial Group’s Galectin Therapeutics GALT Stock Holding History

Jefferies Financial Group’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,188
Closed -$34K – 1795
2026
Q1 		$34K Sell
12,188
-4,247
-26% -$12.9K ﹤0.01% 1661
2025
Q4 		$68.4K Sell
16,435
-865
-5% -$4.55K ﹤0.01% 1741
2025
Q3 		$73.3K Buy
+17,300
New +$65.1K ﹤0.01% 1368

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jefferies Financial Group's GALT Position: Q2 2026 in Review

Jefferies Financial Group sold out of Galectin Therapeutics (GALT) in Q2 2026, closing a stake of 12,188 shares — an estimated $34K sold.

Jefferies Financial Group first reported a position in GALT in Q3 2025 and held it in 3 quarters. The position peaked at $73.3K in Q3 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Jefferies Financial Group reported no remaining Galectin Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 12,188 Galectin Therapeutics shares in Q2 2026, an estimated $34K.
  • Jefferies Financial Group first reported a position in Galectin Therapeutics in Q3 2025 and held it in 3 quarters.
  • Jefferies Financial Group's Galectin Therapeutics position peaked at $73.3K in Q3 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.